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Abstract: 
 
Actovegin is a biological drug produced from deproteinised hemodialysate of calf serum 
with over 50 years of history for its clinical use. There have been many in vitro studies to 
speculate its potential role and mechanism of action in cells; due to the nature of this drug 
and serum based culture techniques for most in vitro experiments, presumptuous 
conclusions and claims from these studies on performance enhancement should be 
cautiously interpreted. There have been well-designed human in vivo studies suggesting it 
does not enhance human performance, and has potentially good clinical applications to 
treat injuries, strokes and diabetes. Recently, evidence has emerged suggesting Actovegin 
has anti-inflammatory and anti apoptotic effects on injured tissues; further clinical research 
is needed to define these effects. This article also provides a narrative review of Actovegin 
summarizing outcomes from recent publications.  
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Muscle injuries are common in sport and are best treated using a regime of rest, 
immobilization, compression and physical therapy[7]. However, this so-Đalled ͞kŶoǁledge͟ 
is based upon long-standing convention and expert opinion, which at best could be 
classified as level 4 evidence. It has been suggested that injection therapy might have a role 
to play in the treatment of muscle injuries[7,14]. Different treatment options such as 
growth factors have been explored and have demonstrated encouraging therapeutic 
results[7]. However, due to anabolic properties, treatment approaches incorporating 
growth factors, autologous blood and autologous conditioned serum are prohibited by the 
World Anti-Doping Agency (WADA)[22].  
 
Injection Therapy 
Recent developments in Sports Medicine have led to many substances being used in the 
context of injection therapy[11].  Platelet rich plasma (PRP) and autologous conditioning 
serum (ACS) have become popular substances of choice for injection therapies – it is alleged 
that such treatments facilitate muscle healing by optimizing provision of growth factors 
involved in the regeneration of muscle, as demonstrated by several animal 
studies[12,13,16]. A recent double-blind, randomized controlled trial by Reurink et al found 
that there were no statistical or clinical differences between their PRP and placebo groups 
in the treatment of muscle injuries[16]. Further, there are currently no universally accepted 
PRP preparation protocols to ensure consistent concentration and quality control between 
individual injections. The principle of using blood products as a drug to treat muscle is not 
new, as biological drugs form a major part of pharmaceutical drug development. As 
medicine has evolved and scientific knowledge continues to develop, a number of ͞older 
drugs͟ could be used in the effective treatment of acute muscle injuries.  
 
Actovegin 
Actovegin (Takeda Pharmaceutical Company Ltd, Osaka, Japan) is a biological drug produced 
from deproteinised haemodialysate of calf serum with a high standard of quality control.  
(figure 1) There are over 50 years of history for its clinical use with much in-vitro as well as 
clinical evidence to support its efficacy[1]. Indeed, the role of calf blood derivatives have a 
well established role in the maintenance of cellular viability and survival in vitro, for 
example, it is commonly used in the form of foetal bovine serum (FBS) supplement in tissue 
  
  
culture medium, and the success of many in-vitro experiments is dependent on the batch of 
FBS employed. Therefore, Actovegin can be viewed as a highly controlled and approved 
form of FBS with an excellent clinical track record for use in human participants.   
 
Figure 1: Actovegin Solution for injection 
 
 
As noted above, the active component(s) and mechanisms of action of Actovegin have yet 
to be identified. There is limited supporting evidence concerning the role it might play in the 
treatment of muscle injuries, and there is no objective evidence pertaining to its properties 
as an ergogenic aid. Several published clinical studies have investigated its role in muscle 
injuries with promising results [10,15].  Anecdotally, an unpublished case series with Dr. 
Hans-Wilhelm Müller-Wohlfahrt’s AĐtoǀegiŶ, that used a mixture injection regimen, seems 
to have produced encouraging results, and many high-profile athletes have endorsed the 
use of Actovegin for the treatment of muscle injuries. Recently, Lee et al reported on the 
effects of standalone Actovegin injection therapy, which reduced return to play time in 
injured, professional footballers[10]. 
 
  
  
  
Recent controversies on Actovegin  
Actovegin has recently received a great deal of media attention in the field of Sports 
Medicine. In addition to its use in the treatment of injury, many anecdotal testimonies have 
suggested that Actovegin is ergogenic, and has the potential to improve athletic 
performance. In December 2000 the International Olympic Committee (IOC) banned 
Actovegin under the classification of blood-doping agents. However, two months later the 
IOC lifted the ban as no indisputable evidence demonstrated that Actovegin had ergogenic 
properties[21].  In a study with 567 diabetic patients, no improvement of muscle strength or 
condition was found after treatment with Actovegin infusion for 160 days [24]. A more 
recent study by Lee et al[9] has provided evidence that Actovegin does not have the 
potential to enhance athletic performance.  These investigators performed a blinded, 
crossover peak aerobic capacity study in healthy human participants with intravenous 
Actovegin compared to placebo saline solution as well as a baseline control. No significant 
differences were observed in peak values for aerobic power, blood lactate concentration 
and blood glucose concentration. Additionally, values of gross and net efficiency, and 
calorific energy equivalents associated with VO2 were similar[9].Their results, therefore, 
confirmed that a maximum, permitted intravenous dose of Actovegin did not improve 
human peak aerobic capacity[9]. Currently, neither intravenous nor intramuscular injections 
of Actovegin are prohibited in or out of competition according to the latest search in the 
Global Drug Reference Online, which is approved by UK Anti-Doping (UKAD), the Canadian 
Centre for Ethics in Sport (CCES), the United States Anti-Doping Agency (USADA) and WADA 
[3,22].  
 
Recent science on Actovegin  
As a deproteinised hemodialysate, Actovegin does not contain peptide, growth factors or 
hormone-like substances[17]. Many studies have attempted to identify the active 
ingredients in Actovegin, but have been unsuccessful. Studies in vitro have suggested that 
Actovegin promotes oxidative metabolism and shifts the redox-balance of the cells in the 
direction of oxidized substrates, which might protect against hypoxic cell injury[17]. The 
most important goal of any post-ischaemic therapeutic strategy is the early interruption of 
the process of cell-damaging events and, ultimately, the avoidance of cell death. Because 
Actovegin promotes oxidation and energy production, its efficacy was assumed to benefit 
  
  
post-ischaemic metabolic events. However, current experimental results from a series of 
studies with human macrophages by the authors using RT-PCR and flow cytometry have 
tentatively demonstrated a possible role of Actovegin as an anti-inflammatory agent: this is 
consistent with the finding that Actovegin can reduce the recovery time in mild muscle 
injuries.  Furthermore, incubation of human muscle biopsies with Actovegin resulted in the 
up-regulation of a number of genes including the anti-apoptotic gene TNFRSF1b. More 
research would be required to ascertain the biological roles of Actovegin in inflammation 
and cell survival, ďut these authors’ ǁork has iŶdiĐated additioŶal roles of Actovegin not 
directly related to cellular metabolism. 
 
Søndergård et al suggested in their in vitro study with human skeletal tissue, that Actovegin 
can affect mitochondrial oxidative function which is similar to many other in vitro studies 
with different cell types. However, they also made unsubstantiated, speculative claims that 
this finding could be translated to performance enhancement in humans. The muscle cells in 
their experiment were treated with a cocktail of chemicals as well as a cytotoxic detergent, 
saponin, which damages the cells’ membrane[19]. Saponin is extremely poisonous to 
marine creatures, and it can be used as a cytotoxic chemotherapy drug in the treatment of 
cancers with major side effects[20]. It stimulates both the Th1 immune response and the 
production of cytotoxic T-lymphocytes, with the serious side-effects of haemolysis of the 
cells[20]. Clinically, saponin has been used in clinical trials but toxicity associated with sterol 
complexation remains a major problem[18,20]. Therefore, the experiment performed by 
Søndergård et al  should be viewed as an in vitro cell membrane injury study, similar to the 
scenario of grade I or II muscle injuries, but most certainly should not be interpreted as a 
performance-based study [19]. As mentioned earlier, work in vivo by Lee et al[9] has shown 
Actovegin did not improve human peak aerobic capacity.  Therefore, the in vitro finding 
from Søndergård et al [19] will not necessarily translate to improve performance in terms of 
aerobic capacity in humans. Nevertheless, results from this study were interesting as they 
suggested Actovegin had an effect on injured human muscle tissue, which further supports 
the clinical use of intramuscular Actovegin injections therapy for injuries as used by Lee et al 
in their clinical study using a group of professional footballers[10].  
 
  
  
Although the exact mechanism of action of this biological drug is yet to be fully understood, 
recent in vitro studies suggest that it has a positive effect on different injured cell types 
ranging from neuroblastoma cells[23], neutrophils[5] and renal cells[6]. It is clear that 
Actovegin is not a performance enhancing substance, but has an excellent profile to 
promote cell repair[1,8]. Further scientific effort of this drug should, therefore, be focused 
on its application in clinical medicine such as the ARTEMIDA study in patients with post-
stroke cognitive impairment[4], wound healing and in the treatment of skeletal muscle 
injuries[1].  
 
Injection therapy with Actovegin for soft tissue injuries  
The use of intramuscular Actovegin injections in the treatment of muscle tears was first 
published by Pfister and Koller[15]. Their partially blinded, case control study included 103 
patients, and demonstrated a reduction in recovery time from 8.3 weeks for the control 
group to 5.5 weeks in their treatment group[15]. However, patients in this study were 
recruited from a wide variety of sports and at different competitive levels. A criticism of this 
study relates to the fact that the treatment regimen and rehabilitation protocols employed 
were not fully standardised, and Actovegin was mixed with local anaesthetics before being 
injected; it is, therefore, possible that this would have altered the pharmacodynamics and 
pharmacokinetics of the drug. The final outcomes were based on subjective observations 
made by patients and clinicians, and there was no objective pre-injury data to compare 
outcome characteristics to. Lee et al[10] published a study associated with the 
intramuscular injection of Actovegin used to treat grade I hamstring injuries. Players in the 
Actovegin treatment group were able to return to play 8 days earlier compared to 
physiotherapy alone (P = 0.033)[10]. The patients in this study were professional football 
players from the same club, hence their physical fitness was comparable and the 
rehabilitation protocol used was standardised[10].  
 
It is evident, that Actovegin has been clinically used for more than 60 years, and it is evident 
that the oral, topical, intravenous and intramuscular administration of the drug is safe[1]. 
Many official governing bodies including WADA, UKAD, CCES and USADA do not prohibit its 
use. However, it should be noted that Actovegin is not on the British National Formulary and 
  
  
Medicines and Healthcare products Regulatory Agency in the UK, and the Food and Drug 
Administration in the USA has not approved its use.  
 
Conclusion  
 
The career lifespan of a professional athlete is often short lived, and a shortened recovery 
time could translate to increased game play and benefit to the team and club. Due to the 
unique relationship between sports physicians and athletes, individuals are often under 
pressure to seek the latest ͞aĐtiǀe͟ or ͞ĐuttiŶg edge͟ treatŵeŶts[2], and athletes are often 
not interested in being part of a Clinical Trial. Therefore, it is not always possible to recruit a 
large sample of participants who are professional athletes. There is also much publicity 
about the use of Actovegin as an ergogenic aid, but such assumptions are founded on 
speculative and questionable anecdotal evidence. Actovegin is not licensed to treat muscle 
or soft tissue injuries, and the evidence relating to its effectiveness in this regard is limited. 
CritiĐs haǀe suggested that AĐtoǀegiŶ is ŶothiŶg ŵore thaŶ ͞sŶake oil͟[2]. Nevertheless, 
there is published evidence demonstrating its potential for clinical efficacy and safety 
[4,10,24]. 
 
Sport-related muscle injuries are very common, and result in significant morbidity and time 
lost from training and competitions. Recently, a number of novel treatment options have 
appeared in the market place. The use of platelet-rich plasma (PRP) and Actovegin has 
attracted significant interest in Sports Medicine. Although evidence is limited for both of 
these substances, PRP has received many so-called ͞expert opinioŶs͟ aŶd its use has ďeeŶ 
encouraged. In contrast, views associated with the use of Actovegin are somewhat more 
tainted, but with the exception of subjective, anecdotal opinion, there is no clear evidence 
that Actovegin has any ergogenic qualities. Evidence based medicine is an important aspect 
in modern medicine; we must not reject treatment base on limited evidence. However, we 
should be cautious in our consideration and interpretation of available evidence, strike a 
balance between potential risk and benefit associated with treatment, and tailor the use of 
any therapeutic intervention to the individual athlete’s Ŷeeds. 
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